Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

Histiocyte-rich B-cell lymphoma

Written2010-07Antonio Cuneo, Gian Matteo Rigolin, Francesco Cavazzini
Hematology Section, Department of Biomedical Sciences, University of Ferrara, Corso Giovecca 203, Ferrara, Italy

(Note : for Links provided by Atlas : click)

Identity

ICD-Topo C420,C421,C424 BLOOD, BONE MARROW, & HEMATOPOIETIC SYS
Atlas_Id 2071

Clinics and Pathology

Disease T-cell/histiocyte-rich large B cell lymphoma (THRLBCL) is a distinct entity of aggressive lymphoma, recognized by the WHO classification as a separate entity (2008), in which few scattered neoplastic cells (usually <5%) are surrounded by reactive T-lymphocytes and histiocytes. THRLBCL shares several morphological and immunophenotypic similarities with nodular lymphocyte-predominant Hodgkin's lymphoma (Pittaluga et al., 2010). These two entities may share initial transforming events that occur at germinal center B cell, followed by early divergence in the evolution of the neoplastic process (Franke et al., 2002).
Phenotype / cell stem origin The postulated normal counterpart is a germinal centre B cell.
The immunophenotype of the neoplastic component in pan-B positive, BCL6+, CD15-, CD30-.
Epidemiology It accounts for a minority of diffuse large B-cell lymphoma (<10%).
Clinics The disease runs an aggressive course and is usually associated with poor outcome in those patients presenting at an advanced stage.
Pathology The lymph node section shows scattered large cells surrounded by many lymphocytes and histiocytes. The disease must be distinguished from nodular lymphocyte-predominant Hodgkin's lymphoma, which has distinct clinical features.
Treatment Chemoimmunotherapy using anti CD20 monoclonal antibody rituximab in combination with CHOP or CHOP-like regimens is the standard of care (El Weshi et al., 2007).
Prognosis A >80% overall response rate was obtained by chemoimmunotherapy, with a 5-year overall survival of approximately 50% (El Weshi et al., 2007).

Cytogenetics

Cytogenetics Molecular Because of the low number of neoplastic cells, there are technical problems in obtaining evaluable metaphase chromosomes in THRLBCL. Tetraploid clones with complex aberrations, including a 14q32 translocation, were described in the absence of BCL6, BCL2 or c-myc involvement (La Starza et al., 1996; Wang et al., 2005; de Leval et al., 2006).
The presence of the PAX5/IGH gene rearrangement was demonstrated by fluorescence in situ hybridization (FISH) to represent a recurrent aberration (Poppe et al., 2005).
An average of 4.7 genomic imbalances/case were detected by comparative genomic hybridization in 17 cases of THRLBCL. The most frequently detected imbalances included gain of Xq (59%, minimal overlapping region Xq12q13), 4q (41%, minimal overlapping region 4q25q26), Xp (29%, minimal overlapping region Xp21p11), and 18q (24%, minimal overlapping region 18q21), as well as loss of 17p (24%) (Franke et al., 2002).

Bibliography

T cell/histiocyte-rich large B-cell lymphoma.
De Wolf-Peeters C, Delabie J, Campo E, Jaffe ES, Delsol G.
Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, ed. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. WHO press, 4th ed. Lyon: IARC. 2008; pp 238-239.
 
T-cell/histiocyte-rich B-cell lymphoma: Clinical presentation, management and prognostic factors: report on 61 patients and review of literature.
El Weshi A, Akhtar S, Mourad WA, Ajarim D, Abdelsalm M, Khafaga Y, Bazarbashi S, Maghfoor I.
Leuk Lymphoma. 2007 Sep;48(9):1764-73. (REVIEW)
PMID 17786712
 
Comparative genomic hybridization pattern distinguishes T-cell/histiocyte-rich B-cell lymphoma from nodular lymphocyte predominance Hodgkin's lymphoma.
Franke S, Wlodarska I, Maes B, Vandenberghe P, Achten R, Hagemeijer A, De Wolf-Peeters C.
Am J Pathol. 2002 Nov;161(5):1861-7.
PMID 12414532
 
14q+ chromosome marker in a T-cell-rich B-cell lymphoma.
La Starza R, Aventin A, Falzetti D, Stul M, Martelli MF, Falini B, Mecucci C.
J Pathol. 1996 Feb;178(2):227-31.
PMID 8683394
 
T-cell/histiocyte-rich large B-cell lymphoma.
Pittaluga S, Jaffe ES.
Haematologica. 2010 Mar;95(3):352-6.
PMID 20207840
 
PAX5/IGH rearrangement is a recurrent finding in a subset of aggressive B-NHL with complex chromosomal rearrangements.
Poppe B, De Paepe P, Michaux L, Dastugue N, Bastard C, Herens C, Moreau E, Cavazzini F, Yigit N, Van Limbergen H, De Paepe A, Praet M, De Wolf-Peeters C, Wlodarska I, Speleman F.
Genes Chromosomes Cancer. 2005 Oct;44(2):218-23.
PMID 15942942
 
T-cell/histiocyte-rich large B-cell lymphoma displays a heterogeneity similar to diffuse large B-cell lymphoma: a clinicopathologic, immunohistochemical, and molecular study of 30 cases.
Wang J, Sun NC, Chen YY, Weiss LM.
Appl Immunohistochem Mol Morphol. 2005 Jun;13(2):109-15.
PMID 15894921
 
T-cell/histiocyte-rich large B-cell lymphoma associated with a near-tetraploid karyotype and complex genetic abnormalities.
de Leval L, Harris NL, Lampertz S, Herens C.
APMIS. 2006 Jun;114(6):474-8.
PMID 16856972
 

Citation

This paper should be referenced as such :
Cuneo, A ; Rigolin, GM ; Cavazzini, F
T-cell/histiocyte-rich large B cell lymphoma
Atlas Genet Cytogenet Oncol Haematol. 2011;15(4):358-359.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Anomalies/TrichLargBCLID2071.html


External links

arrayMap (UZH-SIB Zurich)
COSMICHisto = - Site = haematopoietic_and_lymphoid_tissue (COSMIC)
arrayMap[select an item]
 
 
Disease databaseHistiocyte-rich B-cell lymphoma
REVIEW articlesautomatic search in PubMed
Last year articlesautomatic search in PubMed
All articlesautomatic search in PubMed


© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Mon Sep 18 17:20:27 CEST 2017


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.